7 completed, 1 recruiting. 8 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 7, Recruiting 1 |
| Phase 1 | 5 | Completed 4, Recruiting 1 |
Follow Rickets, Hypophosphatemic: new trials by email Literature Review of Rickets, Hypophosphatemic trials Research Report on Rickets, Hypophosphatemic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia KK8123 - X-linked Hypophosphatemia | Phase 1 / Phase 2 | Recruiting | Kyowa Kirin Co., Ltd. | 39 | 2024-10-09 | 2026-11-06 |
| Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of Age Burosumab - X-linked Hypophosphatemia (XLH) | Phase 1 / Phase 2 | Completed | Kyowa Kirin Pharmaceutical Development Ltd | 16 | 2020-02-26 | 2024-11-07 |
| Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH) Burosumab - X-Linked Hypophosphatemia | Phase 2 | Completed | Kyowa Kirin, Inc. | 13 | 2016-05-05 | 2024-05-06 |
| Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH) KRN23 - X-Linked Hypophosphatemia | Phase 2 | Completed | Kyowa Kirin, Inc. | 20 | 2015-01-30 | 2024-05-06 |
| Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH) burosumab - X-linked Hypophosphatemia | Phase 2 | Completed | Kyowa Kirin, Inc. | 52 | 2014-07-02 | 2024-05-06 |
| An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia KRN23 - X-linked Hypophosphatemia | Phase 1 / Phase 2 | Completed | Kyowa Kirin Co., Ltd. | 23 | 2012-02-01 | 2024-06-18 |
| A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia KRN23 - X-linked Hypophosphatemia | Phase 1 / Phase 2 | Completed | Kyowa Kirin Co., Ltd. | 29 | 2011-04-01 | 2024-06-18 |
| Growth Hormone Treatment in Children With Hypophosphatemic Rickets norditropine simplex - X Linked Hypophosphatemic Rickets | Phase 1 / Phase 2 | Completed | Bicetre Hospital | 19 | 2006-01-01 | 2016-03-28 |
Familial Hypophosphatemic Rickets (8) · Bone Diseases (1) · Hypophosphatemia (1) · Kidney Diseases (1) · Metabolic Diseases (1) · Musculoskeletal Diseases (1) · Rare Diseases (1)
Avitaminosis (8) · Bone Diseases, Metabolic (8) · Calcium Metabolism Disorders (8) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (8) · Deficiency Diseases (8) · Female Urogenital Diseases (8) · Female Urogenital Diseases and Pregnancy Complications (8) · Genetic Diseases, Inborn (8) · Hypophosphatemia, Familial (8) · Male Urogenital Diseases (8) · Malnutrition (8) · Metabolism, Inborn Errors (8) · Metal Metabolism, Inborn Errors (8) · Nutrition Disorders (8) · Nutritional and Metabolic Diseases (8)
burosumab (6) · Growth Hormone (1)
Kyowa Kirin Co., Ltd. (3) · Kyowa Kirin, Inc. (3) · Bicetre Hospital (1) · Kyowa Kirin Pharmaceutical Development Ltd (1)
United States (6) · Canada (3) · France (3) · Spain (2) · United Kingdom (2) · Austria (1) · Germany (1) · Italy (1) · Netherlands (1) · Sweden (1)
Amy Zhang, PhD (2)
PMID 25919461, PMID 32721016, PMID 39151033, PMID 26073451, PMID 28822957, PMID 29791829, PMID 30638856, PMID 34636899, PMID 36072994, PMID 42044650